2022
DOI: 10.1007/978-1-0716-2505-7_17
|View full text |Cite
|
Sign up to set email alerts
|

Radioiodine Refractory Differentiated Thyroid Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 39 publications
0
1
0
Order By: Relevance
“…So far, RAI has been the most often used additional treatment for patients with intermediate- or high-risk of disease recurrence or metastatic DTC ( 55 ). However, patients with advanced DTC either have inherent resistance or develop resistance to this treatment ( 56 ). Additionally, MTC and anaplastic TC do not exhibit a valuable response to RAI therapy due to their inability to metabolize iodine.…”
Section: Discussionmentioning
confidence: 99%
“…So far, RAI has been the most often used additional treatment for patients with intermediate- or high-risk of disease recurrence or metastatic DTC ( 55 ). However, patients with advanced DTC either have inherent resistance or develop resistance to this treatment ( 56 ). Additionally, MTC and anaplastic TC do not exhibit a valuable response to RAI therapy due to their inability to metabolize iodine.…”
Section: Discussionmentioning
confidence: 99%